Earli exists to make cancer a benign experience. Earli does that by turning cancers against themselves: genetically forcing them to reveal themselves early, and then kill themselves – precisely and clearly distinguishable from benign lesions at early stages. Based on original technology from Stanford’s renowned Gambhir lab, Earli designs genetic constructs that are injected intravenously that turn cancer cells against themselves. These programmable synthetic promoter-reporter sequences “flip on” like light switches only in dysregulated cancer cells and turn them into "factories." The cancer is forced to produce either an epitope “docking station” for imaging agents, or a cytokine for immune system activation against the tumor. Thus, Earli’s platform enables immediate diagnosis and treatment of early cancers, rather than long-term observation that can lead to deadly metastatic recurrence. Earli's synthetic target expression platform has evolved over five years of deep bioengineering. The system can now detect broad ranges of patient mutations, distinguish between malignant and benign lesions, and offer independence from often elusive natural biomarkers. Who You Are You share our same sense of dedication, scientific passion and entrepreneurial spirit You work well in a fast-paced and extremely focused startup environment You are not only smart, but clever and constantly think outside the box You are able to make logical decisions in an instant when there is little time to evaluate You are a natural communicator and relationship builder You stay calm under high pressure and stress You have the ability to multi-task in a serious way, with an extreme attention to detail You become a representative of the core DNA of the company through who you are The Position Earli is currently seeking a Head of Translational Biology to oversee and lead the translational/in vivo biology group. The successful candidate will have a proven track record of successfully initiating and managing pharmacology and translational science projects across oncology indications from Discovery through IND enabling studies. She/he will be responsible for working with the existing scientific leadership for the design and planning of in vivo preclinical studies to characterize the efficacy, PK/PD and safety properties of Earli’s proprietary compounds . This position will report to the Chief Scientific Officer.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Executive
Education Level
Ph.D. or professional degree
Number of Employees
11-50 employees